Examkin

Soru

Zorluk: ZorInfectious Diseases

A 6262-year-old man with poorly controlled type 2 diabetes mellitus is admitted to the hospital with a non-healing ulcer on the plantar aspect of his right foot. The ulcer is surrounded by 44 cm of erythema and warmth. During physical examination, a sterile metal probe easily reaches the underlying bone. His temperature is 38.2∘C38.2^\circ\text{C} (100.8∘F100.8^\circ\text{F}), blood pressure is 130/80130/80 mm Hg, and pulse is 9696/min. Laboratory studies show a leukocyte count of 14,500/mm314,500/\text{mm}^3. He is started on empiric intravenous vancomycin and piperacillin-tazobactam. A bone biopsy is performed on the second day of admission. By day 55, his fever has resolved, and the erythema has significantly decreased. The bone biopsy cultures grow only Staphylococcus aureus, which is sensitive to oxacillin, cefazolin, and clindamycin, but resistant to penicillin. No Gram-negative bacilli or anaerobes are isolated. Which of the following is the most appropriate next step in pharmacotherapy?

  1. Discontinue the current regimen and begin intravenous cefazolinCevap
  2. B
    Continue the current regimen of intravenous vancomycin and piperacillin-tazobactam
  3. C
    Discontinue intravenous vancomycin and continue intravenous piperacillin-tazobactam
  4. D
    Discontinue intravenous piperacillin-tazobactam and continue intravenous vancomycin
  5. E
    Discontinue the current regimen and begin oral ciprofloxacin and clindamycin

Cevap

Discontinue the current broad-spectrum regimen and begin intravenous cefazolin to specifically target Methicillin-Susceptible Staphylococcus aureus (MSSA).
The correct answer is to discontinue the broad-spectrum regimen and begin intravenous cefazolin. This patient presented with a diabetic foot infection complicated by osteomyelitis, which appropriately prompted empiric therapy with vancomycin and piperacillin-tazobactam. The gold standard for diagnosing the causative organism in osteomyelitis is a bone biopsy. The culture unequivocally identified Methicillin-Susceptible Staphylococcus aureus (MSSA) as the sole pathogen, with no Gram-negative or anaerobic organisms isolated. According to the core principles of antimicrobial stewardship, therapy must be de-escalated to the most narrow-spectrum, effective agent once culture and susceptibility data are available. Intravenous cefazolin (or an anti-staphylococcal penicillin such as nafcillin) is the treatment of choice for MSSA osteomyelitis because it is highly efficacious, narrow-spectrum, and avoids the selective pressure for multi-drug resistant organisms.

Adım Adım Çözüm

1
Identify the primary diagnosis and clinical scenario.
The patient has a diabetic foot ulcer with underlying osteomyelitis (indicated by a positive probe-to-bone test), initially appropriately treated with empiric broad-spectrum antibiotics.
To establish the baseline clinical state and the original indication for broad-spectrum therapy.
2
Interpret the definitive diagnostic data.
Bone biopsy culture at day 5 shows exclusively Staphylococcus aureus that is sensitive to oxacillin, confirming it is Methicillin-Susceptible S. aureus (MSSA).
Bone biopsy is the gold standard for defining the microbiology of osteomyelitis, superseding the initial assumption of a polymicrobial infection.
3
Apply principles of antimicrobial stewardship.
The empiric broad-spectrum coverage (vancomycin and piperacillin-tazobactam) must be de-escalated to target only MSSA.
To prevent antibiotic resistance, reduce toxicity, and provide the most efficacious targeted therapy for the specific pathogen isolated.
4
Select the optimal definitive pharmacotherapy.
Intravenous cefazolin is chosen.
Cefazolin is a first-generation cephalosporin and the drug of choice for severe MSSA infections, providing narrow-spectrum, highly bactericidal activity.

Anahtar Kavram

Antimicrobial stewardship dictates the de-escalation of empiric broad-spectrum antibiotics to targeted, narrow-spectrum therapy based on definitive culture results; intravenous cefazolin (or an anti-staphylococcal penicillin) is the treatment of choice for MSSA osteomyelitis.
Bu soruyu puanla

Konular

Infectious Diseases

Bu konudan daha fazla soru